Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Connect Biopharma Holdings Ltd (CNTB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CNTB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -61.55% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 34.44M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 48030 | Beta -0.47 | 52 Weeks Range 0.55 - 2.31 | Updated Date 04/1/2025 |
52 Weeks Range 0.55 - 2.31 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -88.66% | Operating Margin (TTM) 24.64% |
Management Effectiveness
Return on Assets (TTM) -12.13% | Return on Equity (TTM) -17.92% |
Valuation
Trailing PE - | Forward PE 0.77 | Enterprise Value -76696581 | Price to Sales(TTM) 1.43 |
Enterprise Value -76696581 | Price to Sales(TTM) 1.43 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.19 | Shares Outstanding 55254000 | Shares Floating 14791504 |
Shares Outstanding 55254000 | Shares Floating 14791504 | ||
Percent Insiders 41.16 | Percent Institutions 44.85 |
Analyst Ratings
Rating 4.5 | Target Price 7 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Connect Biopharma Holdings Ltd
Company Overview
History and Background
Connect Biopharma Holdings Ltd. is a global clinical-stage biopharmaceutical company founded in 2012. They are focused on discovering and developing therapies for inflammatory diseases and autoimmune disorders. Initially focused on the Chinese market, they expanded globally. Connect Biopharma faced financial challenges and ultimately delisted from the NASDAQ.
Core Business Areas
- Inflammatory Disease Therapies: Focuses on developing novel therapies for chronic inflammatory diseases such as atopic dermatitis and asthma.
Leadership and Structure
Connect Biopharma had a leadership team with experience in pharmaceutical development and commercialization. The organizational structure consisted of research and development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- CBP-201 (Atopic Dermatitis): CBP-201 is an IL-4Ru03b1 antibody being developed for atopic dermatitis. While specific market share data isn't available, competitors include Sanofi/Regeneron (Dupixent) and Leo Pharma. CBP-201 did not progress as expected and contributed to company's issues.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with companies developing innovative therapies for various diseases. It's characterized by high research and development costs and regulatory hurdles.
Positioning
Connect Biopharma aimed to establish itself as a player in the inflammatory disease market by developing differentiated therapies. Their competitive advantage was based on novel targets and approaches.
Total Addressable Market (TAM)
The global atopic dermatitis market is expected to reach billions of dollars. Connect Biopharma aimed to capture a significant share of this market with CBP-201, but faced significant challenges.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets
- Experienced management team
- Clinical-stage pipeline
Weaknesses
- High cash burn rate
- Reliance on single asset (CBP-201)
- Limited commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
Threats
- Competition from established players
- Regulatory setbacks
- Clinical trial failures
Competitors and Market Share
Key Competitors
- SNY
- REGN
- LEO
Competitive Landscape
Connect Biopharma competed against larger, more established pharmaceutical companies with greater resources. Their success depended on demonstrating the superiority of their therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth was driven by clinical development progress. However, the company faced financial difficulties.
Future Projections: Future projections were uncertain due to financial constraints and lack of successful clinical trial outcomes.
Recent Initiatives: Recent initiatives likely involved efforts to secure funding or partnerships.
Summary
Connect Biopharma was a clinical-stage biopharmaceutical company focused on inflammatory diseases. Its future was challenged by its financial performance and its reliance on a single asset. Clinical trial results and securing additional funding were critical for the company. The company's situation was weak due to these factors.
Similar Companies
- SNY
- REGN
- LEO
- VRTS
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry news
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Connect Biopharma Holdings Ltd
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-03-19 | CEO & Director Dr. Barry D. Quart Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 81 | Website https://www.connectbiopharm.com |
Full time employees 81 | Website https://www.connectbiopharm.com | ||
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.